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The term evidence-based medicine (EBM) was first coined
by Dr Gordon Guyatt, a physician and epidemiologist at
McMaster University, Canada.1 He defined EBM as
"medicine practised on the basis of evidence". Soon
after the publication of this single author article in 1991,1
a group of physicians and epidemiologists launched a
campaign by the name of EBM Movement.2 They
emphasised upon greater reliance on up-to-date and
published research; especially, randomised control
trials (RCT) and systematic reviews (SR). Similarly,
evidence based practice is provision of best possible
care to patients by considering their preference, clinical
setting and available best evidence by the trained
healthcare providers. The 28-year journey of EBM is
marked by many success stories. First, it has success-
fully captured the agenda that the scientists and
physicians will decide the future of medicine; and indeed
this is a great achievement.3 Next is foundation of
Cochrane Collaboration in 1993 in Oxford, United
Kingdom by National Health Services (NHS) in which
more than 40,000 volunteers are associated with it, who
are producing more than 400 systematic reviews of
clinical trials annually.4 These systematic reviews are the
bases of formulation of clinical guidelines which are
regularly published by professional societies for good
clinical practice and decision-making. These systematic
reviews also fuel the formulation of appropriate use
criteria (AUC) for judicious use of the procedures and
devices by various professional societies.5 EBM has
recently launched a campaign demanding pharma-
ceutical industry to disclose the data of clinical trials
which have been funded by them. This agenda has
been warmly welcomed and supported by World
Health Organization (WHO) and European Union
(EU).6,7 Recently, EBM has coined a terminology "over-
diagnosis", not leading to reduced mortality associated
with a particular disease.8 This has been observed for
the significantly increased incidence of thyroid and
prostate cancers due to overwhelming use of fine-
needle aspiration in thyroid nodule and serum PSA
without appreciable decline in cancer related mortality.8
It is imperative to improve clinical outcome with respect
to clinical need and cost; and hopefully, EBM campaign
will produce a positive impact.
There are four basic elements of EBM.9 First, a clinical
question is formulated which has four pertinent
information, i.e. Patient, Intervention, Comparison and
Outcome (PICO).10 A PICO question could be like
"Dobutamine stress echocardiography has better
prognostic value than myocardial perfusion imaging for
patients with acute myocardial infarction". For this PICO
question, best available evidences are searched from
available published data in the form of randomised
control trials as these have lower odds of bias; and
studies with good patients' population, reduce the
chances of error. Then these published data are
validated internally and externally. Finally, the results
extracted from validated data are applied in clinical
practice in conjunction with clinical expertise and
patients' preferences. Gathered information about a
PICO question is than issued by the professional society
or body in the form of clinical guidelines.9 Usually, these
clinical guidelines have recommendations for practising
physicians with weightage based on evidences.
The recommendations in clinical guidelines are usually
classified as Class I: having evidence and/or general
agreement about the usefulness / efficacy of a
procedure or treatment; Class II: having conflicting
evidence about the usefulness and efficacy of the
particular procedure or treatment; Class III: there is
evidence of a general agreement that particular
procedure is not useful and effective or may be harmful.
These recommendations are supported by evidence
which is further classified on the basis of its origin.
Evidence drawn from multiple randomised trials are
considered strong (Level A) and those drawn from single
randomised trial or non-randomised trials is considered
fair (Level B). Evidence which is only based on
consensus opinions of experts and not having support
of published data are considered weak (Level C).11
Similarly, this validated evidence is also used for
Appropriate Use Criteria (AUC) for certain clinical
procedures and devices, which are released by
professional societies. A procedure is considered
appropriate for which the expected health benefits
exceed expected risk by a wide margin.5 Contrary to
clinical guidelines, AUC are often consensus of experts'
opinion with a weak scientific basis. There is also a
possibility that if a physician feels that he or she would
be judged on the basis of AUC, it is quite possible that
the physician may use a diagnosis that fits with AUC and
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not the real one for that required procedure. However, it
is also important to understand that there is significant
discordance between AUC published for nuclear
myocardial perfusion imaging from different societies.12
It can be argued whether we have EBM in cardiac
imaging? A recently published study revealed that
medicare billing for medical imaging had increased from
$7 billion in 2000 to $14 billion in 2005.13 Furthermore,
approximately one-third of billing amount involved
cardiovascular medical imaging which were adopted at
an extraordinary cost with insufficient evidence of
benefits to patients.13 Another study published in 2009
revealed that 30-50% of cardiac procedures performed
were appropriate and basic reasons were market
messages, high patient demand and defensive
medicine, leading to the vicious circle of the so-called
Ulysses syndrome.14 However, the most important
concern has been raised by American Heart Association
(AHA) in its scientific statement published in 2014. This
states that the radiation exposure to US population from
medical imaging has increased six-fold since 1980 and
over 40% of this has been contributed by the cardio-
vascular imaging and intervention.15 This important
fact indeed draws attention to sensitize the medical
community about the importance of EBM in cardiac
imaging, particularly to minimize the lifetime attributable
risk for radiation associated cancer in exposees.
It is imperative to understand the possible obstacles in
implementation of EBM in cardiac imaging. The most
important obstacle is over-reliance on the reliability of
clinical trials and systematic reviews. For example, two
systematic reviews about the impact of beta-blockers on
mortality in acute myocardial infarction had totally
different outcomes; one favoured and the other denied
the role of beta blocker in reducing mortality.3 Over-
reliance on statistical significance of results of published
data is another considerable obstacle. Statistical
methods used in analysis need to be carefully studied as
inappropriate use could make a non-significant p-value
to a statistically significant one. Therefore, while reading
published studies, one must consider clinical as well as
statistical significance of data mentioned in a clinical trial
or systematic review. It is also not uncommon to have
incomplete and conflicting recommendations by
professional societies, that clinicians feel to be well away
from real practice. It is also important to understand that
the non-availability of certain equipment and patients'
preferences are also important hurdles in imple-
mentation of EBM in cardiac imaging. Lastly, the
financial aspect, associated with cardiac imaging like
reimbursement by insurance companies or financial
malpractice among referring physicians and cardiac
laboratories, is also an undeniable obstacle.3
For effective implementation of EBM in a cardiac imaging,
a multifaceted approach is considered most appropriate.
We must acquire clinical information from educational
materials, like review articles and meta-analyses, with
recently published guidelines and AUC by the relevant
professional societies. We must educate staff and
physicians about AUC for specific clinical questions.
Studies have shown considerable variation in raters at
different levels of training in identifying inappropriate
nuclear cardiac imaging procedures.16 With appropriate
training, improvements have been observed for appro-
priate use of transthoracic echocardiography (TTE) and
CT angiography (CTA), but not for trans-esophageal
echocardiography (TEE) and stress imaging.17 While
performing cardiac imaging, one must perform complete
evaluation and documentation that procedure meets
relevant AUC criteria. In institute having Picture
Archiving and Communication Systems (PACS),
Computerized Physician Order Entry (CPOE) and
frequent reminders about the importance of appropriate
cardiac imaging procedures, can be installed. When
physician enters an order for a cardiac imaging
procedure, the software asks few clinical queries
pertinent to AUC for that particular imaging. Effective
communication among staff, nurses and referring
physicians can also help by convincing the referring
physician about an appropriate imaging against his or
her patient's clinical query. To address financial issues,
one can link the reimbursement with practice of EBM as
per clinical guidelines and AUC. American Congress has
passed a bill in 2014: "As of 2017, claims without
documentation that AUC criteria were consulted, will not
be paid by medicare".18 It also states that documentation
is the responsibility of the referring physician but the
payment would be at risk for the performing physician
and this has indeed created conflict between them.
Evidence-based medicine has become an explicit
element of medical professionalism, rendering to launch
a successful campaign that physicians and scientists will
decide the future of medicine. It has introduced culture
of clinical guidelines and AUC for better clinical decision-
making in cardiology and other faculties of medicine.
However, it has also contributed tension between the
different sectors of healthcare. Despite these obstacles,
there is optimism for EBM future in cardiac imaging as it
would reduce probability of radiation-associated cancers
by curtailing inappropriate and unjustified radiation-
based procedures. To achieve this aim, there is a
unanimous call for more evidence to support evidence-
based cardiac imaging in future. It is believed that "lack
of evidence does not mean absence of evidence."
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